Mohammad AskarPublic working copy · medical review pending

Secondary open-angle glaucomas · 119

Secondary open-angle glaucoma: identify the cause and protect vision

Distinguish pigment dispersion from glaucoma. Keep the broader original secondary-glaucoma examples in context and plan pressure control,causal treatment and monitoring together.

Public working copy · medical review pending. Source, translation and medical checks remain open. Read the limitations in the text and references. These educational materials do not replace individual medical assessment. Published: 2026-11-18T19:45:52+01:00. Internal project references lead to this notice. They are not publicly accessible primary sources; the source limitations remain stated in the text.

Pigment alone is not glaucoma. Document pressure,nerve,field and angle; treat the actual risk or damage. In secondary disease,identify the cause and any evolving angle closure rather than applying one laser or drug recipe to every eye.

Terminology and draft status

Terminology review is not complete. Selected actual WHO UMD queries and their limits are recorded in terminology.md; they do not approve the whole translation.

01Recognise pigment dispersion and document damage

Pigment dispersion syndrome (PDS) releases iris pigment that can obstruct trabecular outflow and raise intraocular pressure (IOP). Pigmentary glaucoma (PG) requires glaucomatous optic neuropathy; pigment or a pressure rise alone does not establish it. Young or middle-aged myopic men are a familiar presentation, but other patients can be affected. 2

Posterior iris concavity and reverse pupillary block can bring the posterior pigment epithelium into contact with the zonules. Look for a Krukenberg spindle, midperipheral radial iris transillumination and dense trabecular pigment. The signs vary; a Krukenberg spindle is not pathognomonic. 2

Gonioscopy assesses angle width, pigment distribution and secondary mechanisms. A Sampaolesi line is pigment anterior to Schwalbe’s line and also occurs in pseudoexfoliation; it is not a PG-specific diagnostic sign. Document the disc/RNFL, OCT and reliable visual fields to distinguish risk from damage and later progression. 2

An older community cohort estimated conversion at 10% after 5 years and 15% after 15 years. Its retrospective ascertainment, few events and historical endpoint, which included pressure-related treatment, limit transfer to a modern individual diagnosis. These figures are not a universal forecast or a treatment indication. 3

The original grade 3–4 pigment describes an examination scale, not proof of optic-nerve damage. Interpret the scale and distribution with the nerve, field and pressure findings. 1 2

02Choose pressure treatment and assess laser risk

For PG, pressure lowering follows the principles used for other open-angle glaucomas. Set the target from damage, progression and lifetime visual risk; consider medication, suitable laser or surgery. A heavily pigmented angle without relevant pressure risk or damage is not itself an indication for treatment. 2

Selective laser trabeculoplasty (SLT) can cause marked pressure spikes in densely pigmented angles. Use cautious energy selection, appropriate prophylaxis and pressure review for the eye and device. Low power is a principle, not proof that one fixed energy or an inferior-only treatment extent is correct for every PG eye. 2 4

A retrospective matched comparison of 65 PG and 65 POAG eyes recorded early spikes in 5/65 versus 0/65 eyes (p=0.058), despite lower total energy in PG. Few events, different medication patterns and non-random treatment limit precision and causal inference; a non-significant comparison does not establish equal safety. 4

YAG peripheral iridotomy may flatten a concave iris by changing the pressure relationship. Anatomical improvement is not proof that glaucoma or visual-field loss is prevented. Evidence for routine prophylactic iridotomy in PDS/PG is uncertain; selected clinical indications require a separate risk–benefit decision. 2 5

The original 0.3–0.4 mJ and inferior 180° examples remain unverified as a universal pigmentary-glaucoma protocol. The particular eye and laser protocol determine energy, extent, prophylaxis and early review. 1 2 4

Choose pressure treatment and assess laser risk
TreatmentDecision and safety
SLT in dense pigmentCautious individual energy/extent,prophylaxis and pressure review; no universal inferior-only recipe
YAG peripheral iridotomyMay alter iris configuration; prevention of glaucoma/field loss not established for routine prophylaxis

03Recognise pseudoexfoliation and plan for zonular weakness

Pseudoexfoliative glaucoma (PEXG, also PXFG) is an important secondary open-angle form with substantial geographical variation. Fibrillar material affects trabecular outflow and the zonules; associated systemic findings do not prove one systemic treatment for the ocular disease. Look for a central lens-capsule disc, a clear intermediate zone and a peripheral material ring. 2

Phacodonesis, poor dilation and zonular weakness change the cataract plan. Prepare suitable pupil-expansion tools and capsule/zonular support, such as selected hooks or a tension ring, according to the defect. Distinguish pupil hooks from support of the capsular bag; no single device guarantees against capsular rupture or lens loss. 2

Pressure can be high and fluctuate, and progression risk may exceed that of POAG. Reassess the target and follow-up rather than using pigment density as a guarantee of laser success. Medication and laser can help but may lose effect; cataract extraction is not automatically sufficient glaucoma treatment. 2

04Treat neovascular glaucoma and its ischaemic cause urgently

Neovascular glaucoma (NVG) can begin with an open angle covered by abnormal vessels and progress to synechial closure as a fibrovascular membrane contracts. Consider proliferative diabetic retinopathy, ischaemic central retinal vein occlusion (CRVO) and ocular ischaemic syndrome (OIS). Examine iris and angle vessels and the posterior segment; a particular pressure number is not required to recognise the threat. 2 10 13 14

Pain, corneal oedema, visual potential and angle closure determine urgency and the pressure plan. Coordinate medical pressure lowering, inflammation/pain control and appropriate glaucoma procedures with treatment of retinal ischaemia. Do not postpone dangerous-pressure management simply to follow a rigid laser-first sequence. 2 10 14

Anti-VEGF can produce rapid but temporary neovascular regression; it does not reverse established synechiae. Panretinal photocoagulation (PRP) addresses the retinal angiogenic drive when indicated and feasible. Timing and delivery depend on retinal disease, visibility and the whole eye; neither a fixed spot count nor a small central “island” is a universal treatment recipe. 2 10 14

Suspected ocular ischaemic syndrome also needs assessment of carotid and systemic vascular disease with the appropriate team. Local eye treatment alone does not address the underlying hypoperfusion. Retinal and glaucoma management should follow the cause rather than treating every NVG presentation as the same disease. 13

The original pressure examples of 70 or 57 mmHg illustrate urgent disease, not thresholds below which NVG is safe. Do not transfer the original 3000–4000 PRP spots or preservation of only a 1–2-disc-diameter island into a universal destructive laser plan; treat the retinal indication and dangerous pressure in parallel. 1 2 10 14

05Separate inflammation, viral disease and Fuchs syndrome

Inflammatory debris, trabeculitis, synechiae and steroid exposure can all raise pressure in uveitis. Determine whether the angle is open or closing and whether the inflammation is infectious. Control indicated inflammation and pressure together; reducing essential anti-inflammatory treatment without a plan can worsen the disease. 2

Fuchs uveitis syndrome may show diffuse iris atrophy, stellate keratic precipitates and mild chronic anterior inflammation with or without vitritis. The affected iris can look lighter, but heterochromia can be absent or hard to see; colour alone cannot identify the diseased eye. Typical Fuchs disease does not routinely benefit from chronic corticosteroid treatment; cataract and glaucoma need specific care. 6

Posner–Schlossman-like recurrent unilateral pressure attacks can be associated with cytomegalovirus (CMV), but prevalence varies by population and phenotype is not diagnostic. Consider selected aqueous testing when it will change management. SUN research classification relies on aqueous CMV PCR; it is not evidence that every clinical attack is CMV or that a test has perfect sensitivity. 2 7

Suspected or confirmed herpetic/CMV disease requires pathogen-appropriate antiviral planning alongside indicated inflammation and pressure treatment. Do not treat presumed viral inflammation with unprotected corticosteroid monotherapy. Corneal epithelial infection and stromal/anterior uveitic disease require different decisions; involve the relevant specialist. 2 7

The original CMV proportion of 50–75% depends on the selected population and remains source-unmatched here; aqueous PCR is not 100% sensitive in every attack. A negative sample and a Fuchs-like appearance require clinical interpretation rather than an automatic exclusion or diagnosis. 1 2 7

06Assess steroid risk and monitor implants

Steroid pressure response depends on potency, route, dose, duration and individual susceptibility. A pressure rise and established steroid glaucoma are different outcomes; a general percentage of “high responders” cannot be transferred between topical drops, implants and diseased eyes. Review baseline nerve status, previous response and all steroid exposure. 2 8 9

SAFODEX retrospectively reviewed 421 eyes of 361 patients receiving dexamethasone implants. Ocular hypertension occurred in 28.5% of eyes over mean follow-up of 16.8 months, using a pressure or pressure-rise definition. Selected treatment, heterogeneous indications, repeated exposure and absent random controls limit causal and individual-risk interpretation. 8

Predictor findings differ across small retrospective implant cohorts, including the direction of age associations. In a 2025 series, pressure elevation followed 40/171 implants in 74 eyes; missed early visits, available-case analysis and repeated eyes/implants complicate interpretation. These data do not establish comparative long-term superiority of a particular pressure procedure. 8 11 12

The EU Ozurdex information contraindicates use in advanced glaucoma inadequately controlled by medication alone and in specified infection/capsule configurations. Check the actual label and the eye before treatment. Monitor pressure after injection and through the steroid-effect period; retinal thickness alone is not a substitute for glaucoma-risk assessment or follow-up. 9

If pressure rises, coordinate necessary inflammation control with pressure treatment. Consider a weaker steroid, steroid-sparing therapy or other changes only when suitable for the underlying disease; do not abruptly stop essential treatment without a plan. Persistent damage risk may require laser or surgery, with joint retina/uveitis/glaucoma care. 2 9

Neither the original 30–40% high-responder rate nor a 400 µm retinal-thickness cutoff is a verified universal rule for steroid selection. Prior pressure response, nerve status, product contraindications and follow-up matter even when the macula is thick. 1 2 8 9

07Look for trauma, ICE and lens mechanisms

Angle recession involves injury between longitudinal and circular ciliary-body muscle fibres and may appear as a widened ciliary-body band. Compare sectors and the fellow eye. Gonioscopy is important after trauma but must not be performed on a suspected open globe; acute injury may require delayed angle examination. 2

Traumatic pressure elevation can result from blood, inflammation, lens injury or permanent outflow damage, and glaucoma can appear years later. Treat the current mechanism and arrange long-term surveillance when angle damage remains; a normal pressure today does not remove the later risk. 2

Iridocorneal endothelial (ICE) syndrome involves abnormal endothelial membrane growth onto angle/iris, producing iris distortion and peripheral anterior synechiae. It is commonly unilateral and can cause secondary angle closure. Assess cornea, pupil, iris and angle together; management depends on pressure, visual potential and the affected structures. 2

Phacolytic glaucoma results from leaked lens proteins/inflammatory material obstructing outflow around a mature cataract. Phacomorphic disease is a crowded-angle mechanism from an enlarged lens and is not simply another open-angle form. Recognise the distinction and coordinate pressure/inflammation control with definitive lens management. 2

08Plan monitoring and act on warning signs

For PDS without damage, establish baseline pressure, disc/OCT and field findings, and individualise review for pressure variability and other risk. With PG or another secondary glaucoma, reassess target, adherence and reproducible progression. New symptoms after activity or dilation, treatment changes and prior spikes can justify earlier assessment. 2

A practical plan names the mechanism, the pressure and retinal/inflammatory treatment, the next review and the emergency contact. Check new iris/angle vessels, zonular weakness and infectious clues rather than treating all secondary disease as one label. Reassess after each intervention; a quiet appearance is not proof that the cause or progression has resolved. 2 9 10 14

Sudden severe pain, blurred or reduced vision, marked redness or a painful postoperative/pressure event needs urgent assessment. Acute pressure spikes can occur despite a slowly evolving pigment syndrome. Distinguish the emergency from routine long-term surveillance and do not delay because the patient is young. 2

Plan monitoring and act on warning signs
MechanismFindingWhat to checkTreatment principle
PGMyopia/pigment and possible spikesGonioscopy plus disc/field damageIndividual pressure target; selected medication/laser/surgery with spike precautions
PEXGLens material pattern,pressure fluctuationPupil and zonules as well as glaucoma damagePressure treatment and a specific cataract/support plan when indicated
NVGNew iris/angle vessels,possible painRetinal ischaemia,angle,pressure and visual potentialTreat angiogenic drive and pressure together; temporary injection effect does not replace retinal treatment
Uveitic/Fuchs contextInflammatory signs or iris atrophyDistinguish Fuchs,viral disease and steroid responseCause-specific care plus pressure control; no blanket chronic-steroid regimen
TraumaticTrauma history,widened ciliary bandSafe-timed gonioscopy,lens/blood/inflammationTreat mechanism and pressure; long-term surveillance for permanent angle damage
What are the main learning points?

Pigment alone is not glaucoma. Document pressure,nerve,field and angle; treat the actual risk or damage. In secondary disease,identify the cause and any evolving angle closure rather than applying one laser or drug recipe to every eye.

When is assessment urgent?

Sudden severe eye pain with blurred or reduced vision needs urgent eye assessment. A slowly evolving pigment syndrome does not exclude an acute pressure spike; do not wait for the next routine visit.

References and access status

  1. 1
    Immutable original export; own archived lecture; recording and attribution unverified

    Complete export read; original attribution and any recording/transcript or appointment not independently verified.

  2. 2
    EGS Terminology and Guidelines for Glaucoma,6th edition (2025)

    Historical access documented in the source review, carried forward after editorial rereading on14November2026; no fresh retrieval of the underlying report claimed. Supplied PDF: selected angle/trauma p84,PEX/PG/lens pp129–131,uveitis/trauma/steroid pp132–135 and NVG/ICE p152 text. General target/monitoring appraisal carried from011. No complete-book or new figure inspection claimed.

  3. 3
    Siddiqui et al. PDS conversion cohort (2003),PMID12788118

    Historical access documented in the source review, carried forward after editorial rereading on14November2026; no fresh retrieval of the underlying report claimed. Complete indexed primary abstract read; main report unread. Historical retrospective community cohort; endpoint definitions and few events limit modern individual-risk transfer.

  4. 4
    PG/POAG matched SLT cohort (2024),PMID38470322

    Historical access documented in the source review, carried forward after editorial rereading on14November2026; no fresh retrieval of the underlying report claimed. Complete indexed primary abstract read; full methods/report unread. Retrospective matching,small event counts,different acetazolamide use and eye/patient structure limit safety/causal inference.

  5. 5
    Cochrane. Peripheral iridotomy for pigmentary glaucoma (2016),PMID26871761

    Historical access documented in the source review, carried forward after editorial rereading on14November2026; no fresh retrieval of the underlying report claimed. Indexed abstract/selected results appraisal carried from011; complete review/primary trials unread. Very-low-certainty evidence and anatomical versus functional outcomes remain distinct.

  6. 6
    SUN. Classification criteria for Fuchs uveitis syndrome (2021),PMID33845007

    Historical access documented in the source review, carried forward after editorial rereading on14November2026; no fresh retrieval of the underlying report claimed. Complete indexed primary abstract,selected primary introduction/discussion and extracted classification table read; full report/figure pixels unread. Consensus-selected research classification is not a universal diagnostic test.

  7. 7
    SUN. Classification criteria for CMV anterior uveitis (2021),PMID33845019

    Historical access documented in the source review, carried forward after editorial rereading on14November2026; no fresh retrieval of the underlying report claimed. Complete indexed primary abstract,selected methods/results/discussion and extracted tables inspected; full report/supplements/figure pixels unread. Research case selection and required PCR do not measure routine clinical test sensitivity.

  8. 8
    Malclès et al. SAFODEX (2017),DOI10.1097/IAE.0000000000001369

    Historical access documented in the source review, carried forward after editorial rereading on14November2026; no fresh retrieval of the underlying report claimed. Complete indexed primary abstract read; full report/tables unread. Retrospective,heterogeneous indications,eye-based denominator and repeated exposure; OHT is not a universal high-responder rate.

  9. 9
    EMA. Ozurdex EU product information

    Historical access documented in the source review, carried forward after editorial rereading on14November2026; no fresh retrieval of the underlying report claimed. Official PDF retrieved locally after web429; SmPC sections4.3/4.4 directly read,including contraindications,migration and IOP monitoring. Not every section/language or current device IFU inspected.

  10. 10
    RCOphth. Retinal vein occlusion guideline executive summary (January2022)

    Historical access documented in the source review, carried forward after editorial rereading on14November2026; no fresh retrieval of the underlying report claimed. Official PDF selected neovascular/established-NVG recommendations pp4–5 read. Cover says January2022,review due January2025;2026 hosting path is not a new guideline edition. CRVO-specific context,not every NVG cause.

  11. 11
    Choi and Kwon. Dexamethasone OHT risk cohort (2020),PMID32792579

    Historical access documented in the source review, carried forward after editorial rereading on14November2026; no fresh retrieval of the underlying report claimed. Complete indexed primary abstract and selected indexed methods/result passages read; direct PMC challenged; full report unread. Small retrospective DME cohort,limited events and local thresholds.

  12. 12
    Xiao and Qiu. Ozurdex OHT management cohort (2025),DOI10.1016/j.ajoc.2025.102274

    Historical access documented in the source review, carried forward after editorial rereading on14November2026; no fresh retrieval of the underlying report claimed. Complete indexed primary abstract,selected main methods/results/limitations and extracted table2 inspected. Full narrative/supplements/figure pixels unread. Available-case follow-up and repeated eyes/implants require caution; no random procedure comparison.

  13. 13
    Terelak-Borys et al. Ocular ischaemic syndrome review (2012),PMID22847215

    Historical access documented in the source review, carried forward after editorial rereading on14November2026; no fresh retrieval of the underlying report claimed. Complete indexed review abstract and selected indexed summary passages read; full review/source studies unread. Historical review for cause/differential context,not a newly verified revascularisation protocol.

  14. 14
    AAO. Retinal Vein Occlusions Preferred Practice Pattern,previously inspected hosted PDF

    Historical access documented in the source review, carried forward after editorial rereading on14November2026; no fresh retrieval of the underlying report claimed. Official PDF retrieved locally after browser403. Selected natural-history,treatment and examination text printed pp315–317 read; full PPP/figures/tables not read. Cover approval September2024; a footnote updated through June2026. Filename2026 is not proof of a wholly new approval.

Original lecture link